Evidence map›Paper›PMID 41313527›Full record

ArticleDiscover oncology2025

Integrated analysis of the oncogenic value of CPNE3 in non-small cell lung cancer.

Pei Pang, Lanxin Tian, Jianjie Zhu, Yuanyuan Zeng, Xiaoyu Xu, Li Lin, Shenhua Chen, Jian-An Huang, Wenwen Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pei Pang *Department of Pathology, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Lanxin Tian *Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jianjie ZhuDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yuanyuan ZengDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Xiaoyu XuNational Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Li LinDepartment of Radiology, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Shenhua ChenDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jian-An HuangDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China. huangjianan@suda.edu.cn.
Wenwen DuDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China. duwenwen@suda.edu.cn.

Funding

the Natural Science Foundation of the Jiangsu Higher Education Institutions of China 22KJB320006the Natural Science Foundation program of the First Affiliated Hospital of Soochow University No bxqn202236This work was supported by grants from the National Natural Science Foundation of China 82100170This work was supported by grants from the National Natural Science Foundation of China 82202886
6 · The paper itself

Abstract

backgroundVasculogenic mimicry (VM) is correlated with higher tumor grade, cancer cell metastasis and invasion, and poorer prognosis in lung cancer patients. CPNE3 reportedly acts as an oncogene to promote tumorigenesis. However, whether CPNE3 regulates VM in NSCLC remained largely unknown.

methodsIn the present study, TCGA database and GEPIA2 web server were selected to explore CPNE3 expression in lung cancer tissues, which was verified via qRT-PCR analysis. The Kaplan-Meier plotter and PrognoScan web servers were used to assess the effect of CPNE3 expression on patient survival. The cBioPortal platform was used for genetic mutation analysis. Transwell assay, three-dimensional culture and western blot were used to confirm the role and mechanism of CPNE3 in mediating VM and cell metastasis. Finally, ssGSEA and TISIDB were applied for immune infiltration analysis.

resultsWe found that among all CPNEs, high expression of CPNE3 was valuable for predicting OS in lung cancer patients, and was associated with advanced TNM stages. Missense substitution partially led to the expression alteration of CPNE3 gene. CPNE3 can promote VM formation and cell metastasis via EMT process. However, a weak correlation was found between CPNE3 expression and immune cell infiltration levels.

conclusionsCPNE3 regulates tumor cell migration, invasion, VM formation and immune evasion by acting as an oncogene in NSCLC, implying that CPNE3 can serve as a potential anti-angiogenesis target for NSCLC.

Indexed as

AngiogenesisCPNE3Immune infiltrationNon-small cell lung cancerPrognosis

Identifiers

PMID41313527
PMCPMC12662914

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.